Skip to content

Erin Mauney

6 papers in the library · 34 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Psychological Adverse Effects of Psychedelic Use.

The Primary Care Companion For CNS Disorders June 25, 2026 Franklin King, Juliana Zambrano, Erin Mauney et al.

The Psychiatric Consultation Service at Massachusetts General Hospital sees medical and surgical inpatients with comorbid psychiatric symptoms and conditions. During their twice-weekly rounds, Dr Stern and other members of the Consultation Service discuss diagnosis and management of hospitalized patients with complex medical or surgical problems who also demonstrate psychiatric symptoms or...

Medical Complications of Psychedelics.

The Primary Care Companion For CNS Disorders June 23, 2026 Franklin King, Brian S. Barnett, S Trevor Taylor et al.

The Psychiatric Consultation Service at Massachusetts General Hospital sees medical and surgical inpatients with comorbid psychiatric symptoms and conditions. During their twice-weekly rounds, Dr Stern and other members of the Consultation Service discuss diagnosis and management of hospitalized patients with complex medical or surgical problems who also demonstrate psychiatric symptoms or...

Erin Mauney: Psychedelics as modulators of the gut-brain interaction

Psychedelics June 3, 2025 Erin Mauney

Dr. Erin E. Mauney serves as Assistant Professor of Pediatrics (Gastroenterology) at Tufts University while maintaining a research appointment at Massachusetts General Hospital. With dual board certification, including obesity medicine, she integrates clinical expertise with innovative research at the intersection of gut-brain disorders and psychedelic medicine. Dr. Mauney's groundbreaking work...

Psychedelic-assisted therapy: An overview for the internist

Cleveland Clinic Journal of Medicine March 1, 2025 Franklin King, Brian S. Barnett, Erin Mauney 11 citations

Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin-may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid...

Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome

Journal of Clinical Gastroenterology February 17, 2025 Erin Mauney, Franklin King, Helen Burton-Murray et al. 3 citations

Irritable bowel syndrome (IBS) is prevalent and can be disabling. Many patients remain symptomatic despite behavioral and medical therapies. Psychedelic-assisted therapy (PAT), in which serotonergic agents like psilocybin are administered in a psychotherapeutic context, has shown promise for refractory psychiatric disorders, including major depressive disorder and post-traumatic stress...

Practical considerations in the establishment of psychedelic research programs.

Psychopharmacology 2025 Brian S. Barnett, M Frances Vest, Marcus S Delatte et al. 20 citations

There is increasing interest in establishing psychedelic research programs at academic medical centers. However, psychedelics are intensely psychoactive, carry considerable sociopolitical baggage, and most are Schedule I drugs, creating significant potential impediments to implementation. There is little formal guidance for investigators on navigating the complex on-the-ground obstacles...